Spruce Biosciences (NASDAQ:SPRB) and Endonovo Therapeutics (OTCMKTS:ENDVD) Financial Analysis

Spruce Biosciences (NASDAQ:SPRB) and Endonovo Therapeutics (OTCMKTS:ENDVD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Earnings and Valuation

This table compares Spruce Biosciences and Endonovo Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-$38.97 million	($36.60)	-1.50
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A

Endonovo Therapeutics has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

91.7% of Spruce Biosciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Spruce Biosciences and Endonovo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	2	7	0	2.60
Endonovo Therapeutics	0	0	0	0	0.00

Spruce Biosciences currently has a consensus price target of $163.00, indicating a potential upside of 197.42%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Spruce Biosciences is more favorable than Endonovo Therapeutics.

Risk and Volatility

Spruce Biosciences has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.

Profitability

This table compares Spruce Biosciences and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

Summary

Spruce Biosciences beats Endonovo Therapeutics on 7 of the 13 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.